Improving the manufacturing process for gene therapy vectors.
Official title: Resubmission - Development and scale-up of Continuous Countercurrent Tangential Chromatography (CCTC) for next generation AAV vector manufacturing (Direct to Phase II)
Funded at Chromatan Corporation · NIH-11084537 · Data updated 2026-11-12
This study is testing a new way to make gene therapies better and more affordable by improving how we purify the viral vectors used in treatments for serious conditions like cancer and hemophilia, so patients can get the help they need more easily.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Chromatan Corporation NIH-funded |
| Lab location | 1 site (Dedham, United States) |
| Project start | May 15, 2024 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $695,448 |
| NIH project number | 5R44GM154572-02 |
| Project ID | NIH-11084537 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research are patients with conditions treatable by gene therapies, such as cancer and hemophilia.
✕Less likely to help
Patients with conditions that are not addressed by AAV-based therapies may not receive any benefit from this research.
What this research studies
This research focuses on developing a new method called Continuous Countercurrent Tangential Chromatography (CCTC) to purify adeno-associated viral vectors (AAVs) used in gene therapies. By creating a column-free and continuous purification process, the research aims to enhance the efficiency and quality of AAV production, which is crucial for treating serious conditions like cancer and hemophilia. Patients can benefit from this innovative approach as it promises to reduce production costs and improve the availability of effective therapies. The methodology involves advanced bioprocessing techniques to streamline the purification of these vital biological agents.
Why it matters
Potential benefit: If successful, this research could lead to more effective and accessible gene therapies for patients with serious health conditions.
How similar studies have gone: Other research has shown promise in improving bioprocessing techniques for biologics, indicating that this approach could lead to significant advancements in the field.
Where this research is happening
-
Chromatan Corporation
Dedham, United States Active
Researchers
- Principal investigator: Shinkazh, Oleg — Chromatan Corporation
- Study coordinator: Shinkazh, Oleg
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.